PRCSG News

   Annual Meeting in Chicago, IL

 ACR 2018 ABSTRACTS / POSTERS

 

  • Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Systemic Juvenile Idiopathic Arthritis. Session Date/Time: October 23; 4:30 PM - 6:00 PM. Presentation time: 5:00 PM - 5:15 PM

 

  • Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis. Session Date/Time: October 23; 9:00 AM - 11:00 AM

 

  • The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations among Patients with Juvenile Idiopathic Arthritis enrolled in the STRIVE Registry. Session Date/Time: October 23; 9:00 AM - 11:00 AM

 

  • Long-term Disease Control Among Patient with Juvenile Idiopathic Arthritis Receiving Adalimumab Treatment for up to Six Years. Session Date/Time: October 23; 9:00 AM - 11:00 AM

 

  • Subcutaneous Abatacept in Patients Aged 2 - 17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results Over 24 Months by Juvenile Idiopathic Arthritis Disease Category. Session Date/Time: October 23; 9:00 AM - 11:00 AM

 

  • Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus.                                   Session Date/Time: October 23; 4:30 PM - 6:00 PM

 

  • New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis.                               Session Date/Time: October 21; 4:30 PM - 6:00 PM

 

     

 NEW - FDA approves subcutaneous formulation of ACTEMRA for systemic JIA

 

Revised Common Rule: educational videos created by OHRP

 

May 2018 - FDA approves subcutaneous formulation of Actemra for use is Polyarticular Juvenile Idiopathic Arthritis

 

March 2017 - Subcutaneous abatacept now available for patients with JIA. link